Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label, safety study of cetuximab and differing dose levels of dasatinib in
adult patients with advanced solid malignancies. Cetuximab will be administered as an
intravenous infusion weekly. Dasatinib will be taken orally, once a day, on a continuous
schedule at differing dose levels. The primary objective of this study is to determine the
toxicities and the maximum tolerated doses of dasatinib when combined with cetuximab for the
treatment of advanced solid tumors.